Aspect Biosystems appoints trio to board

Biotechnology company Aspect Biosystems has announce the appointment of three new members to its Board of Directors: Dr Nancy Krieger, Dr Don Haut and Dr Devyn Smith.

The company develops bioprinted tissue therapeutics to transform how diseases are treated.

Dr Don Haut is currently the CEO of discovery-stage, non-viral gene therapy company Carmine Therapeutics.

Originally trained as a molecular biologist before joining McKinsey, Dr Haut has since held senior business roles at 3M Company, Smith & Nephew, The Medicines Company, Promedior, Histogenics, Sherlock Bio and AskBio.

Dr Haut said:

“When I first learned about what Aspect Biosystems was doing, my first thought was ‘Wow!’”

“My second thought was ‘it would be great to work with those folks – they are really onto something.’

“So, I am delighted to be joining Aspect – the team, the technology, and the mission are all outstanding.”

Dr Nancy Krieger is the Chief Medical Officer of late-clinical stage cell therapy biotech Talaris Therapeutics.

Dr Krieger has over 18 years of global experience in the biopharmaceutical industry, including leadership positions at Bristol Myers Squibb and Novartis in areas spanning solid organ and stem cell transplantation, immunology, rare disorders, and chronic kidney and liver diseases.

Dr Krieger said:

“I am thrilled to be joining the Board of Aspect Biosystems.

“As a transplant surgeon I am passionate about the tremendous potential of Aspect’s 3D bioprinting technology for regenerative cellular therapies, with the ultimate possibility of replacing organ transplants without the need for life-long immunosuppression.”

Dr Devyn Smith joined Arbor Biotechnologies as CEO in 2021 after concluding his role as COO of Sigilon Therapeutics. Before that, he worked in a variety of roles at Pfizer Inc., including COO of the UK-based Neusentis Unit focused on discovering and developing cell therapies.

Dr Smith said:

“I am excited to join the board of Aspect Biosystems.

“I look forward to partnering with Tamer and the talented team at Aspect to build a successful company that delivers novel cellular therapies to patients with high unmet needs.”